Choom Holdings Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Choom Holdings's earnings have been declining at an average annual rate of -38.1%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 78.6% per year.
Anahtar bilgiler
-38.1%
Kazanç büyüme oranı
-17.6%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 23.1% |
| Gelir büyüme oranı | 78.6% |
| Özkaynak getirisi | n/a |
| Net Marj | -84.1% |
| Son Kazanç Güncellemesi | 31 Dec 2021 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Choom Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Dec 21 | 19 | -16 | 9 | 0 |
| 30 Sep 21 | 21 | -13 | 9 | 0 |
| 30 Jun 21 | 22 | -20 | 9 | 0 |
| 31 Mar 21 | 21 | -15 | 9 | 0 |
| 31 Dec 20 | 18 | -15 | 9 | 0 |
| 30 Sep 20 | 13 | -19 | 10 | 0 |
| 30 Jun 20 | 7 | -20 | 10 | 0 |
| 31 Mar 20 | 4 | -16 | 10 | 0 |
| 31 Dec 19 | 2 | -16 | 11 | 0 |
| 30 Sep 19 | 0 | -12 | 12 | 0 |
| 30 Jun 19 | 0 | -11 | 12 | 0 |
| 31 Mar 19 | 0 | -13 | 12 | 0 |
| 31 Dec 18 | 0 | -10 | 10 | 0 |
| 30 Sep 18 | 0 | -8 | 8 | 0 |
| 30 Jun 18 | 0 | -6 | 5 | 0 |
| 31 Mar 18 | 0 | -3 | 2 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
| 30 Sep 17 | 0 | -1 | 0 | 0 |
| 30 Jun 17 | 0 | -1 | 0 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | -1 | 0 | 0 |
| 30 Sep 16 | 0 | -1 | 0 | 0 |
| 30 Jun 16 | 0 | -1 | 0 | 0 |
| 31 Mar 16 | 0 | -1 | 0 | 0 |
| 31 Dec 15 | 0 | -1 | 0 | 0 |
Kaliteli Kazançlar: CHOO is currently unprofitable.
Büyüyen Kar Marjı: CHOO is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CHOO is unprofitable, and losses have increased over the past 5 years at a rate of 38.1% per year.
Büyüme Hızlandırma: Unable to compare CHOO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: CHOO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Özkaynak Getirisi
Yüksek ROE: CHOO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.